|
Dr. Drees founded Sanguine Corporation, having worked at the forefront of the blood substitute business for over thirty-four years. Dr. Drees was the President and CEO of Alpha Therapeutics, the only company to obtain FDA approval for a blood substitute product for human use. He has many years of experience with FDA approval, and the development, marketing and management of artificial blood products. Dr. Drees is one of the most experienced individuals in the field of blood substitutes. He has published many articles and a book on the subject of blood substitutes, and has consulted worldwide for the blood industry through Drees International, Inc. He was an officer and Director of the American Blood Resources Association and Blood Commission.
Dr. Drees’ role in the Company is to drive the business technical and regulatory development of PHER-O2. He also holds four patents on fluorocarbon synthetic red blood cells. | 